Enzymotec Stock Price, News & Analysis (NASDAQ:ENZY)

$11.90 0.10 (0.85 %)
(As of 12/13/2017 08:03 AM ET)
Previous Close$11.80
Today's Range$11.80 - $11.90
52-Week Range$6.10 - $12.35
Volume247,800 shs
Average Volume68,679 shs
Market Capitalization$276.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22

About Enzymotec (NASDAQ:ENZY)

Enzymotec logoEnzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Receive ENZY News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commodity Chemicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENZY
CUSIPN/A
Phone972-74-717-7177

Debt

Debt-to-Equity RatioN/A
Current Ratio5.24%
Quick Ratio3.62%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio1,190.00
P/E Growth73.43

Sales & Book Value

Annual Sales$47.70 million
Price / Sales5.85
Cash Flow$0.06 per share
Price / Cash208.91
Book Value$6.00 per share
Price / Book1.98

Profitability

Trailing EPS($0.26)
Net Income$-2,920,000.00
Net Margins-12.32%
Return on Equity-3.26%
Return on Assets-2.99%

Miscellaneous

Employees205
Outstanding Shares23,430,000

Enzymotec (NASDAQ:ENZY) Frequently Asked Questions

What is Enzymotec's stock symbol?

Enzymotec trades on the NASDAQ under the ticker symbol "ENZY."

How were Enzymotec's earnings last quarter?

Enzymotec Ltd. (NASDAQ:ENZY) announced its quarterly earnings results on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.03. The biotechnology company earned $12 million during the quarter, compared to the consensus estimate of $14.23 million. Enzymotec had a negative return on equity of 3.26% and a negative net margin of 12.32%. The firm's revenue was down 14.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.09 EPS. View Enzymotec's Earnings History.

When will Enzymotec make its next earnings announcement?

Enzymotec is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Enzymotec.

Where is Enzymotec's stock going? Where will Enzymotec's stock price be in 2017?

2 brokerages have issued twelve-month price targets for Enzymotec's shares. Their forecasts range from $11.50 to $12.00. On average, they anticipate Enzymotec's share price to reach $11.75 in the next year. View Analyst Ratings for Enzymotec.

What are Wall Street analysts saying about Enzymotec stock?

Here are some recent quotes from research analysts about Enzymotec stock:

  • 1. According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (10/17/2017)
  • 2. Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)

Who are some of Enzymotec's key competitors?

Who are Enzymotec's key executives?

Enzymotec's management team includes the folowing people:

  • Steve Dubin, Independent Chairman of the Board (Age 60)
  • Erez Israeli, President, Chief Executive Officer (Age 48)
  • Yoav Doppelt, Independent Vice Chairman of the Board (Age 48)
  • Dror Israel, Chief Financial Officer, Vice President (Age 46)
  • Yoav Kahane, Chairman of Advanced Lipids AB (Age 42)
  • Yoni Twito, Chief Operating Officer (Age 47)
  • Naama Zamir, Vice President - Human Resources and Information Systems (Age 43)
  • Gai Ben-Dror, Vice President - Process Development (Age 45)
  • Tzafra Cohen, Vice President - Research & Development (Age 47)
  • Tamar D. Howson, Director (Age 68)

Who owns Enzymotec stock?

Enzymotec's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FRUTAROM LTD (19.13%), FRUTAROM LTD (18.74%), Osborn Williams & Donohoe LLC (0.05%) and JPMorgan Chase & Co. (0.04%). View Institutional Ownership Trends for Enzymotec.

Who bought Enzymotec stock? Who is buying Enzymotec stock?

Enzymotec's stock was acquired by a variety of institutional investors in the last quarter, including Osborn Williams & Donohoe LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Enzymotec.

How do I buy Enzymotec stock?

Shares of Enzymotec can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzymotec's stock price today?

One share of Enzymotec stock can currently be purchased for approximately $11.90.

How big of a company is Enzymotec?

Enzymotec has a market capitalization of $276.45 million and generates $47.70 million in revenue each year. The biotechnology company earns $-2,920,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Enzymotec employs 205 workers across the globe.

How can I contact Enzymotec?

Enzymotec's mailing address is SAGI 2000 INDUSTRIAL AREA P.O. BOX 6, MIGDAL HAEMEQ L3, 2310001. The biotechnology company can be reached via phone at 972-74-717-7177 or via email at [email protected]


MarketBeat Community Rating for Enzymotec (ENZY)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Enzymotec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enzymotec (NASDAQ:ENZY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.75$11.75$8.00$9.00
Price Target Upside: 4.44% upside4.44% upside12.09% downside1.10% downside

Enzymotec (NASDAQ:ENZY) Consensus Price Target History

Price Target History for Enzymotec (NASDAQ:ENZY)

Enzymotec (NASDAQ:ENZY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/30/2017Wells Fargo & CompanyBoost Price TargetMarket Perform$9.50 -> $12.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingHold$11.50N/AView Rating Details
4/17/2016Canaccord GenuityReiterated RatingHoldN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Enzymotec (NASDAQ:ENZY) Earnings History and Estimates Chart

Earnings by Quarter for Enzymotec (NASDAQ:ENZY)

Enzymotec (NASDAQ ENZY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018$0.08N/AView Earnings Details
8/16/20176/30/2017$0.05($0.10)$12.78 million$13.00 millionViewN/AView Earnings Details
5/17/20173/31/2017$0.06$0.03$14.23 million$12.00 millionViewN/AView Earnings Details
2/22/2017Q416$0.03($0.10)$11.47 million$10.60 millionViewN/AView Earnings Details
11/16/2016Q316$0.07$0.03$13.29 million$11.40 millionViewN/AView Earnings Details
8/9/2016Q216$0.08$0.04$14.90 million$15.00 millionViewN/AView Earnings Details
5/19/2016Q116$0.05$0.09$13.85 million$14.00 millionViewListenView Earnings Details
2/17/2016Q415$0.10$0.07$14.01 million$13.30 millionViewListenView Earnings Details
11/11/2015Q315$0.07$0.08$14.21 million$12.40 millionViewListenView Earnings Details
8/12/2015Q215$0.06$0.11$12.39 million$13.40 millionViewListenView Earnings Details
5/7/2015Q115$0.06$0.09$12.10 million$12.25 millionViewN/AView Earnings Details
2/18/2015Q414$0.08$0.06$11.11 million$10.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.04$0.05$10.22 million$9.50 millionViewN/AView Earnings Details
8/5/2014Q214$0.10$0.02$14.88 million$11.50 millionViewN/AView Earnings Details
5/14/2014Q114$0.17$0.24$19.40 million$23.70 millionViewN/AView Earnings Details
2/13/2014Q413$0.11$0.15$11.64 million$18.51 millionViewN/AView Earnings Details
11/11/2013Q313$0.11$0.13$13.10 million$22.50 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Enzymotec (NASDAQ:ENZY) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.00$0.00$0.00
Q3 20171$0.04$0.04$0.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Enzymotec (NASDAQ:ENZY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzymotec (NASDAQ ENZY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Enzymotec (NASDAQ ENZY) News Headlines

Source:
DateHeadline
Enzymotec (ENZY) Shareholders Approve Proposed Acquisition by FrutaromEnzymotec (ENZY) Shareholders Approve Proposed Acquisition by Frutarom
www.streetinsider.com - December 12 at 5:52 PM
BRIEF-Enzymotec Shareholders Approve Proposed Acquisition By FrutaromBRIEF-Enzymotec Shareholders Approve Proposed Acquisition By Frutarom
www.reuters.com - December 12 at 5:52 PM
Merger Deal between Enzymotec and Frutarom Approved by 99.9% Majority of Enzymotec ShareholdersMerger Deal between Enzymotec and Frutarom Approved by 99.9% Majority of Enzymotec Shareholders
finance.yahoo.com - December 12 at 9:52 AM
Analysts Expect Enzymotec Ltd. (ENZY) to Post $0.08 EPSAnalysts Expect Enzymotec Ltd. (ENZY) to Post $0.08 EPS
www.americanbankingnews.com - December 6 at 7:46 PM
Celanese (CE) versus Enzymotec (ENZY) Critical ReviewCelanese (CE) versus Enzymotec (ENZY) Critical Review
www.americanbankingnews.com - November 27 at 7:48 AM
Frutarom Industries (FRUTF) CEO Ori Yehudai on Q3 2017 Results - Earnings Call TranscriptFrutarom Industries' (FRUTF) CEO Ori Yehudai on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 22 at 4:38 AM
Zacks: Enzymotec Ltd. (ENZY) Receives Consensus Rating of "Hold" from BrokeragesZacks: Enzymotec Ltd. (ENZY) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 12:16 PM
Contrasting Enzymotec (ENZY) and PQ Group Holdings (PQG)Contrasting Enzymotec (ENZY) and PQ Group Holdings (PQG)
www.americanbankingnews.com - November 18 at 9:08 PM
Enzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial ResultsEnzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial Results
finance.yahoo.com - November 16 at 1:55 PM
Enzymotec posts 3Q profitEnzymotec posts 3Q profit
finance.yahoo.com - November 16 at 1:55 PM
Enzymotec Ltd. (ENZY) Scheduled to Post Earnings on TuesdayEnzymotec Ltd. (ENZY) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - November 7 at 3:04 AM
Enzymotec Ltd. Calls 2017 Annual And Extraordinary General Meeting Of Shareholders For Approval Of Merger And Other MattersEnzymotec Ltd. Calls 2017 Annual And Extraordinary General Meeting Of Shareholders For Approval Of Merger And Other Matters
www.thestreet.com - November 2 at 7:32 PM
Enzymotec Ltd. Calls 2017 Annual and Extraordinary General Meeting of Shareholders for Approval of Merger and Other MattersEnzymotec Ltd. Calls 2017 Annual and Extraordinary General Meeting of Shareholders for Approval of Merger and Other Matters
finance.yahoo.com - November 2 at 7:32 PM
Wells Fargo & Company Raises Enzymotec Ltd. (ENZY) Price Target to $12.00Wells Fargo & Company Raises Enzymotec Ltd. (ENZY) Price Target to $12.00
www.americanbankingnews.com - October 30 at 9:52 PM
Enzymotec Enters Definitive Agreement to be Acquired by FrutaromEnzymotec Enters Definitive Agreement to be Acquired by Frutarom
finance.yahoo.com - October 29 at 4:40 AM
Frutarom Will Acquire Full Ownership of the Specialty Nutrition Company Enzymotec at a Net Investment of Approx. USD 210MFrutarom Will Acquire Full Ownership of the Specialty Nutrition Company Enzymotec at a Net Investment of Approx. USD 210M
finance.yahoo.com - October 29 at 4:40 AM
Israeli flavour firm Frutarom to buy remaining 81 pct of EnzymotecIsraeli flavour firm Frutarom to buy remaining 81 pct of Enzymotec
finance.yahoo.com - October 29 at 4:40 AM
Sale of NKY health care firm leads to departure of executiveSale of NKY health care firm leads to departure of executive
www.bizjournals.com - October 26 at 1:13 PM
Enzymotec Ltd (ENZY) Rating Reiterated by Jefferies Group LLCEnzymotec Ltd (ENZY) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 22 at 9:06 PM
Enzymotec Ltd. (ENZY) Stock Rating Upgraded by Zacks Investment ResearchEnzymotec Ltd. (ENZY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 17 at 11:38 PM
Enzymotec (ENZY) & Its Peers Financial ComparisonEnzymotec (ENZY) & Its Peers Financial Comparison
www.americanbankingnews.com - October 8 at 8:08 PM
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 5:28 PM
Enzymotec (ENZY) versus Praxair (PX) Head-To-Head ComparisonEnzymotec (ENZY) versus Praxair (PX) Head-To-Head Comparison
www.americanbankingnews.com - October 5 at 6:26 AM
Form SC14D9C Enzymotec Ltd. Filed by: Enzymotec Ltd. - StreetInsider.comForm SC14D9C Enzymotec Ltd. Filed by: Enzymotec Ltd. - StreetInsider.com
www.streetinsider.com - September 27 at 6:33 PM
BRIEF-Enzymotec ltd says on Sept. 24, Steve Dubin, chairman of Enzymotec sent letter to Ori Yehudai, President and ... - ReutersBRIEF-Enzymotec ltd says on Sept. 24, Steve Dubin, chairman of Enzymotec sent letter to Ori Yehudai, President and ... - Reuters
www.reuters.com - September 27 at 6:33 PM
Saxena White P.A. Announces a Proposed Settlement Involving All Persons who Purchased or Otherwise Acquired Enzymotec Common StockSaxena White P.A. Announces a Proposed Settlement Involving All Persons who Purchased or Otherwise Acquired Enzymotec Common Stock
www.businesswire.com - September 25 at 11:25 AM
Enzymotec (ENZY) vs. Its Competitors Critical ContrastEnzymotec (ENZY) vs. Its Competitors Critical Contrast
www.americanbankingnews.com - September 16 at 12:10 AM
Critical Comparison: Enzymotec (ENZY) vs. Innophos Holdings (IPHS)Critical Comparison: Enzymotec (ENZY) vs. Innophos Holdings (IPHS)
www.americanbankingnews.com - September 11 at 8:54 AM
Head to Head Survey: NewMarket Corporation (NEU) and Enzymotec (ENZY)Head to Head Survey: NewMarket Corporation (NEU) and Enzymotec (ENZY)
www.americanbankingnews.com - September 9 at 10:24 AM
Head-To-Head Contrast: Enzymotec (ENZY) & Albemarle Corporation (ALB)Head-To-Head Contrast: Enzymotec (ENZY) & Albemarle Corporation (ALB)
www.americanbankingnews.com - September 1 at 9:10 AM
Enzymotec (ENZY) Reports Acquisition of Five Nurtritional Supplements from Union Springs Healthcare LLCEnzymotec (ENZY) Reports Acquisition of Five Nurtritional Supplements from Union Springs Healthcare LLC
www.streetinsider.com - August 30 at 7:34 PM
Enzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs HealthcareEnzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs Healthcare
finance.yahoo.com - August 30 at 7:34 PM
Enzymotec (ENZY) & Eastman Chemical (EMN) Head-To-Head AnalysisEnzymotec (ENZY) & Eastman Chemical (EMN) Head-To-Head Analysis
www.americanbankingnews.com - August 30 at 6:28 AM
BRIEF-Enzymotec Ltd responds to unsolicited proposal from Frutarom LtdBRIEF-Enzymotec Ltd responds to unsolicited proposal from Frutarom Ltd
www.reuters.com - August 28 at 11:07 PM
Enzymotec Advises Shareholders To Defer Decision On Frutaroms ProposalEnzymotec Advises Shareholders To Defer Decision On Frutarom's Proposal
www.nasdaq.com - August 28 at 11:07 PM
Enzymotec (ENZY) Comments on Unsolicited Proposal from FrutaromEnzymotec (ENZY) Comments on Unsolicited Proposal from Frutarom
www.streetinsider.com - August 28 at 11:07 PM
Corporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic AlternativesCorporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic Alternatives
finance.yahoo.com - August 28 at 6:05 PM
Enzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd.Enzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd.
finance.yahoo.com - August 28 at 6:05 PM
Brokerages Expect Enzymotec Ltd. (ENZY) to Post $0.10 Earnings Per ShareBrokerages Expect Enzymotec Ltd. (ENZY) to Post $0.10 Earnings Per Share
www.americanbankingnews.com - August 25 at 4:50 PM
Frutarom Bought a 9.2% Stake From Paulson, Enzymotec’s Largest Shareholder, to Reach a 19.1% Stake in EnzymotecFrutarom Bought a 9.2% Stake From Paulson, Enzymotec’s Largest Shareholder, to Reach a 19.1% Stake in Enzymotec
finance.yahoo.com - August 24 at 3:42 AM
Jefferies Group Analysts Boost Earnings Estimates for Enzymotec Ltd. (ENZY)Jefferies Group Analysts Boost Earnings Estimates for Enzymotec Ltd. (ENZY)
www.americanbankingnews.com - August 21 at 3:38 AM
BRIEF-Enzymotec Ltd Q2 loss per share $0.10BRIEF-Enzymotec Ltd Q2 loss per share $0.10
www.reuters.com - August 17 at 7:38 PM
Enzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial ResultsEnzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial Results
finance.yahoo.com - August 16 at 4:01 PM
Enzymotec reports 2Q lossEnzymotec reports 2Q loss
finance.yahoo.com - August 16 at 4:01 PM
Enzymotec Ltd. (ENZY) Announces Quarterly  Earnings Results, Misses Estimates By $0.15 EPSEnzymotec Ltd. (ENZY) Announces Quarterly Earnings Results, Misses Estimates By $0.15 EPS
www.americanbankingnews.com - August 16 at 10:38 AM
Enzymotec Ltd. (NASDAQ:ENZY) Scheduled to Post Quarterly Earnings on WednesdayEnzymotec Ltd. (NASDAQ:ENZY) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 9 at 7:18 AM
Quaker Chemical Corporation (KWR) & Enzymotec (ENZY) Head to Head ContrastQuaker Chemical Corporation (KWR) & Enzymotec (ENZY) Head to Head Contrast
www.americanbankingnews.com - August 8 at 10:18 PM
BRIEF-Frutarom reports 9.63 pct stake in Enzymotec ltd ‍ as of August 1BRIEF-Frutarom reports 9.63 pct stake in Enzymotec ltd ‍ as of August 1
www.reuters.com - August 5 at 10:32 PM
BRIEF-Frutarom reports 7.57 pct stake in EnzymotecBRIEF-Frutarom reports 7.57 pct stake in Enzymotec
www.reuters.com - July 31 at 11:05 PM
Enzymotec (ENZY) Announces Appointment of Dror Israel as CFOEnzymotec (ENZY) Announces Appointment of Dror Israel as CFO
www.streetinsider.com - July 29 at 10:30 PM

SEC Filings

Enzymotec (NASDAQ:ENZY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Enzymotec (NASDAQ:ENZY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enzymotec (NASDAQ ENZY) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.